Library
Immune modulationLimited humanResearch only

VIP

Vasoactive Intestinal Peptide

A signalling peptide used off-label intranasally for chronic inflammatory response (CIRS) recovery.

Class

Vasoactive intestinal peptide / immune modulator

Half-life

Very short (~1–2 minutes systemically)

Evidence

Limited human data

Limited human data

Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive.

Overview

VIP is a naturally occurring 28-amino-acid peptide with broad roles in vasodilation, immune regulation, and neuroprotection. In the peptide-therapy world it is best known from the Shoemaker protocol for Chronic Inflammatory Response Syndrome (CIRS, often mold-related), where intranasal VIP is used as a late-stage step to normalise inflammatory markers.

The evidence outside that niche protocol is limited, and even within it the data is largely observational. VIP is a potent vasodilator, so it can lower blood pressure, and its receptors appear on some tumours, which informs its cautions.

How it works

  • Agonises VPAC1/VPAC2 receptors, producing vasodilation and broad anti-inflammatory signalling.
  • Shifts immune activity away from pro-inflammatory Th1/Th17 responses.
  • Neuroprotective and regulatory effects on the HPA axis.

What the research shows

Researched effects

  • Reported normalisation of inflammatory and hormonal markers in CIRS protocols
  • Anti-inflammatory and immune-rebalancing effects
  • Pulmonary and vascular effects from its vasodilatory action

Limitations & what it won't do

  • Evidence is largely from a single niche protocol and is observational.
  • Very short half-life; delivered intranasally for local/CNS effect.
  • Not FDA approved.

Dosing protocols

These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.

Intranasal protocol (CIRS, reference)

~50 mcg per spray
FrequencyUp to 4× daily
RouteIntranasal spray
TimingPer the structured protocol, typically after other steps are complete
CycleExtended, protocol-directed

Used within a specific clinical protocol under supervision. First dose is often done in a clinical setting to watch blood pressure.

Reconstitution & measuring your dose

Handling

Typical vial sizes
5 · 10 mg
Suggested BAC water
2 mL
Storage
Refrigerate; VIP is fragile once reconstituted.
After reconstitution
Reconstituted: use within ~2 weeks; stability is limited.

Why 2 mL? Formulated into a nasal spray rather than injected. A 5 mg vial reconstituted into a metered nasal bottle delivers roughly 50 mcg per actuation depending on the device.

Dose calculator

Draw to

5units

= 0.05 mL · 50 mcg per unit

0u100u

Concentration

5000 mcg/mL

Doses per vial

40

Side effects

Common

  • Flushing
  • Transient blood pressure drop / lightheadedness
  • Nasal irritation
  • Loose stools

Serious / rare

  • Significant hypotension
  • Theoretical concern with VIP-receptor-expressing tumours

Contraindications & interactions

Do not use if you have

  • Pregnant, breastfeeding, or trying to conceive

    No pregnancy safety data.

  • Active cancer or current oncology treatment

    VIP receptors are expressed on some tumours; avoid during active malignancy.

Use caution if you have

  • Cardiovascular disease

    Potent vasodilation can lower blood pressure — caution with cardiovascular disease.

  • High blood pressure

    Blood-pressure-lowering effect requires monitoring, especially with the first dose.

Medication interactions

  • cautionBlood pressure medicationAdditive blood-pressure lowering.
  • cautionNitratesAdditive vasodilation and hypotension risk.
  • cautionPDE5 inhibitorsAdditive hypotension.

What to monitor

  • Blood pressure, especially at initiation
  • Inflammatory markers if used in a CIRS protocol

Commonly combined with

References

Research & educational information only — not medical advice.

You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.

Want to know if VIP fits your goals and history?

The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.

Start the assessment